 Growth Prospects For Western Europe's Generic Drugs Markets
provides newly researched competitive intelligence on 8 key markets: Belgium, France, Germany, Italy, Netherlands, Spain, Switzerland, UK.
The Report highlight opportunities for firms such as India’s Ranbaxy, which bought Romania’s Terapia in 2006 and other Asian firms which are keen to enter this comparatively highly-priced EU generics market via acquisition-based strategies.
Growth Prospects For Western Europe’s Generic Drugs Markets also evaluates key industry trends and growth dynamics, and features BMI’s independent 5-year industry forecasts for each market to end-2012. Each of the 8 generics markets is also ranked according to the competitiveness of the regulatory and business operating environment, and growth potential of the generics segment over the 5-year forecast horizon.
The potential is impressive. BMI values the generics market in the 8 states evaluated at US$27.8bn in 2008, and forecasts a rise of 61.7% to US$46.4bn by 2012. Key growth drivers will be efforts by both public and private healthcare systems to contain costs as aging populations and the increase in chronic diseases impose severe budgetary constraints.
But growth potential is not uniform across the region. Germany is by far the most generics-friendly country, with sales of US$16.3bn in 2007 and anticipated growth of 10%, followed by the UK. While growth rates may be more impressive in Italy and Belgium, the markets are starting from lower bases and, in Italy at least, an embedded culture of opposition to ‘inferior’ generics.
Furthermore, there are risks. The regulatory environment may becoming more pro-generics across the region, but existing support for branded goods in many states may hamper future growth.
| 
